Sirtuins在乳腺癌中作用机制的研究进展

doi:10.11904/j.issn.1002-3070.2021.03.016

摘要/Abstract

摘要： 乳腺癌是女性最常见的恶性肿瘤之一,导致其相关死亡的两大因素是复发转移及多药耐药(Multidrug resistance,MDR)。Sirtuins家族蛋白是一类NAD+依赖性去乙酰化酶,在多种生物学过程及疾病中发挥重要作用,与乳腺癌的发生发展及MDR有关。掌握Sirtuins在乳腺癌的作用机制至关重要,因此本文就Sirtuins家族在乳腺癌中的作用展开综述,讨论Sirtuins家族各亚型对乳腺癌发生发展及MDR的作用机制,并总结目前Sirtuins相关药物的研究进展。

关键词: 乳腺癌, SIRTs, 多药耐药

Abstract: Breast cancer is one of the most common malignant tumors in women.The two major factors leading to its related deaths are recurrence,metastasis and multidrug resistance(MDR).Sirtuins family proteins are a class of NAD+-dependent deacetylases,which play an important role in various biological processes and diseases,and are related to the occurrence and development ofbreast cancer and MDR.It is very important to grasp the mechanism of Sirtuins in Breast cancer.Therefore,this article summarizes the role of Sirtuins in breast cancer,discusses the mechanism of each subtype of Sirtuins family on the occurrence and development of breast cancer and MDR,and summarizes the current research progress of Sirtuins related drugs.

Key words: Breast cancer, SIRTs, Multidrug resistance

中图分类号:

R737.9

李钰莹, 张悦. Sirtuins在乳腺癌中作用机制的研究进展[J]. 实用肿瘤学杂志, 2021, 35(3): 277-281.

LI Yuying, ZHANG Yue. Research progress of Sirtuins in breast cancer[J]. Journal of Practical Oncology, 2021, 35(3): 277-281.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.03.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I3/277

参考文献

1 Kim HM,Koo JS.Clinicopathologic characteristics of breast cancer according to the infiltrating immune cell subtypes[J].Int J Mol Sci,2020,21(12):4438.
2 Kalous KS,Wynia-Smith SL,Summers SB,et al.Human sirtuins are differentially sensitive to inhibition by nitrosating agents and other cysteine oxidants[J].J Biol Chem,2020,295(25):8524-8536.
3 Mautone N,Zwergel C,Mai A,et al.Sirtuin modulators:where are we now? A review of patents from 2015 to 2019[J].Expert Opin Ther Pat,2020,30(6):389-407.
4 Zahedipour F,Jamialahmadi K,Karimi G.The role of noncoding RNAs and sirtuins in cancer drug resistance[J].Eur J Pharmacol,2020,877:173094-173094.
5 He Q,Chen K,Ye R,et al.Associations of sirtuins with clinicopathological variables and prognosis in human ovarian cancer[J].Oncol Lett,2020,19(4):3278-3288.
6 Jin X,Wei Y,Xu F,et al.SIRT1 promotes formation of breast cancer through modulating Akt activity[J].J Cancer,2018,9(11):2012-2023.
7 Xu Y,Qin Q,Chen R,et al.SIRT1 promotes proliferation,migration,and invasion of breast cancer cell line MCF-7 by upregulating DNA polymerase delta1(POLD1)[J].Biochem Biophys Res Commun,2018,502(3):351-357.
8 Yue Y,He L,Tian M,et al.Construction of SIRT1 gene shRNA lentivirus vector and its effect on the proliferation of breast cancer cells[J].Cell Mol Biol(Noisy-le-grand),2020,66(3):204-210.
9 Chung SY,Jung YY,Park HS,et al.Oncogenic role of SIRT1 associated with tumor invasion,lymph node metastasis,and poor disease-free survival in triple negative breast cancer[J].Clin Exp Metastasis,2016,33(2):179-185.
10 Wu M,Wei W,Xiao X,et al.Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer[J].Medical Oncology,2012,29(5):3240-3249.
11 Shi L,Tang XL,Qian MX,et al.A SIRT1-centered circuitry regulates breast cancer stemness and metastasis[J].Oncogene,2018,37(49):6299-6315.
12 Gollavilli PN,Kanugula AK,Koyyada,et al.SAMPK inhibits MTDH expression via GSK 3β and SIRT 1 activation:potential role in triple negative breast cancer cell proliferation[J].FEBS J,2015,282(20):3970-3985.
13 McGlynn LM,Zino S,MacDonald AI,et al.SIRT2:tumour suppressor or tumour promoter in operable breast cancer?[J].Eur J Cancer,2014,50(2):290-301.
14 Shi P,Zhou M,Yang Y.Upregulated tumor sirtuin2 expression correlates with reduced TNM stage and better overall survival in surgical breast cancer patients[J].Irish J Med Sci,2020,189(12):83-89.
15 Zhou W,Ni TK,Wronski A,et al.The SIRT2 Deacetylase stabilizes slug to control malignancy of basal-like breast cancer[J].Cell reports,2016,17(5):1302-1317.
16 Sterneck E,Poria DK,Balamurugan K.Slug and E-cadherin:stealth accomplices?[J].Front Mol Biosci,2020,7:138.
17 He S,He C,Yuan H,et al.The SIRT 3 expression profile is associated with pathological and clinical outcomes in human breast cancer patients[J].Cell Physiol Biochem,2014,34(6):2061-2069.
18 Kenny TC,Craig AJ,Villanueva A,et al.Mitohormesis primes tumor invasion and metastasis[J].Cell Reports,2019,27(8):2292-2303.
19 Neeli PK,Gollavilli PN,Mallappa S,et al.A novel metadherinΔ7 splice variant enhances triple negative breast cancer aggressiveness by modulating mitochondrial function via NFB-SIRT3 axis[J].Oncogene,2020,39(10):2088-2102.
20 Lee JJ,Van de RAH,Zaganjor E,et al.Inhibition of epithelial cell migration and Src/FAK signaling by SIRT3[J].Proc Natl Acad Sci U S A,2018,115(27):7057-7062.
21 Shi Q,Liu T,Zhang X,et al.Decreased sirtuin 4 expression is associated with poor prognosis in patients with invasive breast cancer[J].Oncology Lett,2016,12(4):2606-2612.
22 Greene KS,Lukey MJ,Wang X,et al.SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis[J].Proc Natl Acad Sci U S A,2019,116(52):26625-26632.
23 Uzelac B,Krivokuca A,Brankovic-Magic M,et al.Expression of SIRT1,SIRT3 and SIRT6 genes for predicting survival in triple-negative and hormone receptor-positive subtypes of breast cancer[J].Pathol Oncol Res,2020,26(4):2723-2731.
24 Tang X,Shi L,Xie N,et al.SIRT7 antagonizes TGF-β signaling and inhibits breast cancer metastasis[J].Nat Commun,2017,8(1):318.
25 Huo Q,Li Z,Cheng L,et al.SIRT7 is a prognostic biomarker associated with immune infiltration in luminal breast cancer[J].Front Oncol,2020,10:621.
26 Chen KL,Li L,Yang FX,et al.SIRT7 depletion inhibits cell proliferation,migration,and increases drug sensitivity by activating p38MAPK in breast cancer cells[J].J Cell Physiol,2018,233(9):6767-6778.
27 Tong CWS,Mingxia W,Cho WCS,et al.Recent advances in the treatment of breast cancer[J].Front Onco,2018,8:227.
28 Behzad M,Ali M,Sadaf D,et al.The different mechanisms of cancer drug resistance:a brief review[J].Adv Pharm Bull,2017,7(3):339-348.
29 Wang C,Chen L,Hou X,et al.Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage[J].Nature Cell Biology,2006,8(9):1025-1031.
30 Wang Z,Chen W.Emerging roles of SIRT1 in cancer drug resistance[J].Genes Cancer,2013,4(3/4):82-90.
31 Du ZG,Liu XJ,Chen T,et al.Targeting a Sirt5-Positive subpopulation overcomes multidrug resistance in Wild-Type Kras colorectal carcinomas[J].Cell Reports,2018,23(13):3975-3978.
32 Choi HK,Cho KB,Phuong NTT,et al.SIRT1-mediated FoxO1 deacetylation is essential for multidrug resistance-associated protein 2 expression in tamoxifen-resistant breast cancer cells.[J].Mol Pharm,2013,10(7):2517-2527.
33 Oh WK,Cho KB,Hien TT,et al.Amurensin G,a potent natural SIRT1 inhibitor,rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1[J].Mol Pharmacol,2010,78(5):855-864.
34 Kim HB,Lee SH,Um JH,et al.Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1[J].Oncotarget,2015,6(34):36202-36218.
35 Li K,Ying M,Feng D,et al.Brachyury promotes tamoxifen resistance in breast cancer by targeting SIRT1[J].Biomed Pharmacother,2016,84:28-33.
36 Jin X,Wei Y,Liu Y,et al.High Expression of SIRT1 associates with the doxorubicin resistance of Breast cancer through activating of Akt[J].Anticancer Agents Med Chem,2019,20(1):94-102.
37 Wei Y,Guo Y,Zhou J,et al.Nicotinamide overcomes doxorubicin resistance of breast cancer cells through deregulating SIRT1/Akt pathway[J].Anticancer Agents Med Chem,2019,19(5):687-696.
38 Bourguignon LY,Xia W,Wong G.Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells[J].J Biol Chem,2009,284(5):2657-2671.
39 Zhang L,Ren X,Cheng Y,et al.Identification of Sirtuin 3,a mitochondrial protein deacetylase,as a new contributor to tamoxifen resistance in breast cancer cells[J].Biochem Pharmacol,2013,86(6):726-733.
40 Sinha S,Patel S,Athar M,et al.Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer:an in silico and in vitro study[J].Int J Biol Macromol,2019,140:454-468.
41 Torrens-Mas M,Pons DG,Sastre-Serra J,et al.SIRT3 silencing sensitizes breast cancer cells to cytotoxic treatments through an increment in ROS production[J].J Cell Biochem,2017,118(2):397-406.
42 Xing J,Li J,Fu L,et al.SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL/STAT3 signal pathway[J].Cancer Medicine,2019,8(16):7086-7097.
43 Xu L,Che X,Wu Y,et al.SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer[J].Oncol Rep,2018,39(5):2315-2323.
44 Mattaka K,Yolanda O,Chun G,et al.SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer[J].Carcinogenesis,2013,34(7):1476-1486.
45 Thirumurthi U,Shen J,Xia W,et al.MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer[J].Sci Signal,2014,7(336):71.
46 Mahmud Z,Gomes AR,Lee HJ,et al.EP300 and SIRT1/6 Co-Regulate lapatinib sensitivity via modulating FOXO3-Acetylation and activity in breast cancer[J].Cancers(Basel),2019;11(8):1067.
47 Sociali G,Galeno L,Parenti MD,et al.Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics[J].Eur J Med Chem,2015,102:530-539.
48 Damonte P,Sociali G,Parenti MD,et al.SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects[J].Bioorg Med Chem,2017,25(20):5849-5858.

[1]	提谦, 张清媛. CDK4/6抑制剂联合内分泌治疗晚期乳腺癌[J]. 实用肿瘤学杂志, 2021, 35(3): 287-290.
[2]	杨敏, 张娇燕, 段丹, 徐兵河. 乳腺癌照顾者研究的文献计量学及可视化分析[J]. 实用肿瘤学杂志, 2021, 35(2): 110-116.
[3]	王健宇, 张显玉, 庞达. Luminal A型乳腺癌新辅助化疗疗效的影响因素分析[J]. 实用肿瘤学杂志, 2021, 35(2): 131-136.
[4]	胡洋, 张清媛. PARP抑制剂治疗BRCA1/2突变转移性乳腺癌的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 184-187.
[5]	朱云芳,文洪梅,秦明芳,石青萍,成会荣,高娇,陈杨. 2011—2016年云南省肿瘤登记地区女性乳腺癌发病和死亡情况分析[J]. 实用肿瘤学杂志, 2021, 35(1): 18-22.
[6]	牛明, 于歌. 促进乳腺癌增殖转移和肿瘤干细胞特征的研究[J]. 实用肿瘤学杂志, 2020, 34(6): 518-523.
[7]	刘红, 鲁海玲, 蔡莉. 影像学预测乳腺癌患者预后及新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 535-539.
[8]	袁瑶, 周显礼. 乳腺癌超声特征与腋窝淋巴结转移相关性的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 576-580.
[9]	左婷婷, 吴颖, 董首兰, 曲宁, 高岿然, 李梦丹, 刘运泳. 辽宁省沈阳市城市地区2016-2018年度乳腺癌筛查结果分析[J]. 实用肿瘤学杂志, 2020, 34(5): 387-390.
[10]	郭飘婷, 邹阳. LncRNA SOX2OT海绵吸附miR-34a促进SOX2表达增强大肠癌多药耐药[J]. 实用肿瘤学杂志, 2020, 34(5): 398-403.
[11]	赵仁成, 林子棠, 余卫军, 雷林, 刘峥, 徐英, 郭艳芳, 彭绩. 2017—2019年深圳市宝安区40~74岁常住居民五癌风险流行状况分析[J]. 实用肿瘤学杂志, 2020, 34(4): 315-320.
[12]	仝潇, 邢佳妮, 王丽虹. 长链非编码RNA HCP5通过调控凋亡通路促进三阴性乳腺癌的研究[J]. 实用肿瘤学杂志, 2020, 34(4): 321-327.
[13]	刘思奇, 边娜娜, 苏亚娟. 超声BI-RADS联合血CA15-3和CEA在乳腺肿物诊断中的价值研究[J]. 实用肿瘤学杂志, 2020, 34(4): 347-351.
[14]	张锐, 李志高. 粘液性乳腺癌的临床研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 377-381.
[15]	陈都, 钱诚. 乳腺癌肿瘤微环境中间质细胞介导的化疗耐药性研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 382-386.